Please use this identifier to cite or link to this item: https://doi.org/10.1016/S0039-6257(02)00308-9
Title: Current status of prostaglandin therapy: Latanoprost and unoprostone
Authors: Susanna Jr., R.
Chew, P. 
Kitazawa, Y.
Keywords: Glaucoma
Intraocular pressure
Prostaglandin analog
Uveoscleral outflow
Issue Date: Aug-2002
Citation: Susanna Jr., R., Chew, P., Kitazawa, Y. (2002-08). Current status of prostaglandin therapy: Latanoprost and unoprostone. Survey of Ophthalmology 47 (4 SUPPL. 1) : S97-S104. ScholarBank@NUS Repository. https://doi.org/10.1016/S0039-6257(02)00308-9
Abstract: Latanoprost, a prostaglandin F2α analog prodrug, and unoprostone, an analog of a prostaglandin metabolite, have been shown to be effective in decreasing intraocular pressure when used alone or in combination with other ocular hypotensive agents. The increase in the uveoscleral outflow and some of the side effects are probably FP-receptor mediated, which may account for some differences between the cited drugs. This article reviews the recent literature available on the clinical efficacy of these prostanoids, as well as the studies directly comparing these drugs. © 2002 Elsevier Science Inc. All rights reserved.
Source Title: Survey of Ophthalmology
URI: http://scholarbank.nus.edu.sg/handle/10635/92625
ISSN: 00396257
DOI: 10.1016/S0039-6257(02)00308-9
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

20
checked on Jul 22, 2018

WEB OF SCIENCETM
Citations

17
checked on Jul 4, 2018

Page view(s)

28
checked on Apr 20, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.